“Brief Summary” Format Changes: FDA Gets Proof of Principle In First Study
Executive Summary
FDA will narrow the focus of subsequent studies examining the "brief summary" of risk information in print drug ads to focus on one medical condition following preliminary results from the first study, which considered three different conditions
You may also be interested in...
Can't Please Everybody: FDA's "Brief Summary" Redesign May Require Flexibility
Drug Facts Box format scored well in a broad study, but researchers found it may not be the best format for everyone.